A Phase 1, Open-Label, Single Dose, Randomized, Cross-Over Relative Bioavailability Study Comparing An Oral Liquid Formulation To A Formulated Capsule Of Crizotinib (PF 02341066) In Healthy Volunteers.

Trial Profile

A Phase 1, Open-Label, Single Dose, Randomized, Cross-Over Relative Bioavailability Study Comparing An Oral Liquid Formulation To A Formulated Capsule Of Crizotinib (PF 02341066) In Healthy Volunteers.

Completed
Phase of Trial: Phase I

Latest Information Update: 18 Apr 2012

At a glance

  • Drugs Crizotinib (Primary)
  • Indications Cancer
  • Focus Pharmacokinetics
  • Most Recent Events

    • 18 Apr 2012 Results presented at the 113th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics.
    • 16 Apr 2011 Status changed from recruiting to completed, as reported by ClinicalTrials.gov.
    • 21 Mar 2011 Actual initiation date (Mar 2011) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top